PubMed:27040849 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":84},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":85,"end":98},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":99,"end":288},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":289,"end":374},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":375,"end":393},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":394,"end":606},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":607,"end":716},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":717,"end":728},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":729,"end":920},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":84},"obj":"Sentence"},{"id":"T2","span":{"begin":85,"end":98},"obj":"Sentence"},{"id":"T3","span":{"begin":99,"end":288},"obj":"Sentence"},{"id":"T4","span":{"begin":289,"end":374},"obj":"Sentence"},{"id":"T5","span":{"begin":375,"end":393},"obj":"Sentence"},{"id":"T6","span":{"begin":394,"end":606},"obj":"Sentence"},{"id":"T7","span":{"begin":607,"end":716},"obj":"Sentence"},{"id":"T8","span":{"begin":717,"end":728},"obj":"Sentence"},{"id":"T9","span":{"begin":729,"end":920},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.\nINTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.\nCASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery.\nCONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"27040849-0#51#55#gene1956","span":{"begin":51,"end":55},"obj":"gene1956"},{"id":"27040849-0#64#75#diseaseC0242379","span":{"begin":64,"end":75},"obj":"diseaseC0242379"},{"id":"27040849-0#64#75#diseaseC0684249","span":{"begin":64,"end":75},"obj":"diseaseC0684249"},{"id":"27040849-0#64#75#diseaseC1306460","span":{"begin":64,"end":75},"obj":"diseaseC1306460"},{"id":"27040849-0#20#44#diseaseC0038325","span":{"begin":20,"end":44},"obj":"diseaseC0038325"},{"id":"27040849-1#97#129#gene1956","span":{"begin":196,"end":228},"obj":"gene1956"},{"id":"27040849-1#131#135#gene1956","span":{"begin":230,"end":234},"obj":"gene1956"},{"id":"27040849-1#154#180#diseaseC0007131","span":{"begin":253,"end":279},"obj":"diseaseC0007131"},{"id":"27040849-1#182#187#diseaseC0007131","span":{"begin":281,"end":286},"obj":"diseaseC0007131"},{"id":"27040849-1#154#180#diseaseC0007131","span":{"begin":253,"end":279},"obj":"diseaseC0007131"},{"id":"27040849-1#182#187#diseaseC0007131","span":{"begin":281,"end":286},"obj":"diseaseC0007131"},{"id":"27040849-3#52#56#gene1956","span":{"begin":446,"end":450},"obj":"gene1956"},{"id":"27040849-3#178#181#diseaseC0036391","span":{"begin":572,"end":575},"obj":"diseaseC0036391"}],"relations":[{"id":"51#55#gene195664#75#diseaseC0242379","pred":"associated_with","subj":"27040849-0#51#55#gene1956","obj":"27040849-0#64#75#diseaseC0242379"},{"id":"51#55#gene195664#75#diseaseC0684249","pred":"associated_with","subj":"27040849-0#51#55#gene1956","obj":"27040849-0#64#75#diseaseC0684249"},{"id":"51#55#gene195664#75#diseaseC1306460","pred":"associated_with","subj":"27040849-0#51#55#gene1956","obj":"27040849-0#64#75#diseaseC1306460"},{"id":"51#55#gene195620#44#diseaseC0038325","pred":"associated_with","subj":"27040849-0#51#55#gene1956","obj":"27040849-0#20#44#diseaseC0038325"},{"id":"97#129#gene1956154#180#diseaseC0007131","pred":"associated_with","subj":"27040849-1#97#129#gene1956","obj":"27040849-1#154#180#diseaseC0007131"},{"id":"97#129#gene1956182#187#diseaseC0007131","pred":"associated_with","subj":"27040849-1#97#129#gene1956","obj":"27040849-1#182#187#diseaseC0007131"},{"id":"97#129#gene1956154#180#diseaseC0007131","pred":"associated_with","subj":"27040849-1#97#129#gene1956","obj":"27040849-1#154#180#diseaseC0007131"},{"id":"97#129#gene1956182#187#diseaseC0007131","pred":"associated_with","subj":"27040849-1#97#129#gene1956","obj":"27040849-1#182#187#diseaseC0007131"},{"id":"131#135#gene1956154#180#diseaseC0007131","pred":"associated_with","subj":"27040849-1#131#135#gene1956","obj":"27040849-1#154#180#diseaseC0007131"},{"id":"131#135#gene1956182#187#diseaseC0007131","pred":"associated_with","subj":"27040849-1#131#135#gene1956","obj":"27040849-1#182#187#diseaseC0007131"},{"id":"131#135#gene1956154#180#diseaseC0007131","pred":"associated_with","subj":"27040849-1#131#135#gene1956","obj":"27040849-1#154#180#diseaseC0007131"},{"id":"131#135#gene1956182#187#diseaseC0007131","pred":"associated_with","subj":"27040849-1#131#135#gene1956","obj":"27040849-1#182#187#diseaseC0007131"},{"id":"52#56#gene1956178#181#diseaseC0036391","pred":"associated_with","subj":"27040849-3#52#56#gene1956","obj":"27040849-3#178#181#diseaseC0036391"}],"text":"Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.\nINTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.\nCASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery.\nCONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately."}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":64,"end":68},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":268,"end":272},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":486,"end":490},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.\nINTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.\nCASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery.\nCONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T197","span":{"begin":51,"end":55},"obj":"gene:1956"},{"id":"T198","span":{"begin":64,"end":75},"obj":"disease:C0242379"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T197","obj":"T198"},{"id":"R2","pred":"associated_with","subj":"T197","obj":"T198"},{"id":"R3","pred":"associated_with","subj":"T197","obj":"T198"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.\nINTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.\nCASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery.\nCONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately."}

{"project":"PubCasesORDO","denotations":[{"id":"AB1","span":{"begin":257,"end":279},"obj":"ORDO:70573"},{"id":"AB2","span":{"begin":475,"end":497},"obj":"ORDO:70573"}],"namespaces":[{"prefix":"ORDO","uri":"http://www.orpha.net/ORDO/Orphanet_"}],"text":"Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.\nINTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.\nCASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery.\nCONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":64,"end":68},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":268,"end":272},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":486,"end":490},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.\nINTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.\nCASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery.\nCONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately."}